18 results about "Interstitial fibrosis" patented technology

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

The invention discloses an AI intervention analysis method for diabetic renal interstitial fibrosis, and relates to the technical field of biologication.The method comprises the following specific steps of sample collection and multi-omics data acquisition, specifically, kidney tissue samples of diabetic renal interstitial fibrosis patients before and after the diabetic renal interstitial fibrosis patients use glucose kidney health intervention and kidney tissue samples of healthy contrasts are collected; respectively acquiring epigenetic data and single-cell gene expression data, preprocessing, and integrating to construct a comprehensive data set; by combining the AI technology and the high-throughput epigenetic detection technology, the epigenetic modification change on a TGF-beta1 / Smads signal path in the process of intervening diabetic renal interstitial fibrosis by the Sushenkang can be deeply analyzed; a brand-new perspective is provided for understanding the occurrence mechanism of the diabetic renal interstitial fibrosis disease and the drug action mechanism of the TGF-beta1 / Smads pathway, epigenetic data is deeply mined through AI, and the specific mechanism of the TGF-beta1 / Smads pathway related gene expression affected by the TGF-beta1 / Smads pathway through epigenetic regulation is shown.

To provide a method of treating cardiac fibrosis in a patient.SOLUTION: The present invention relates to a method of treating cardiac fibrosis in a patient, comprising administering to the patient a therapeutically effective amount of an αV-integrin inhibitor. Pharmacological blockade of αV-containing integrins improved cardiac function and survival after MI by reducing infarct size and attenuating expansion of reactive cardiac fibrosis. Notably, after pharmacological blockade of αV-containing integrins, a total myocardial fibrogenesis area as well as interstitial fibrosis in the remote myocardial area are significantly reduced. These data identify a novel mechanism regulating cardiac fibrosis in response to an ischemic injury and suggest that pharmacological targeting of αV-integrins may provide clinical benefit in the treatment of cardiac fibrosis.SELECTED DRAWING: None

The application belongs to the technical field of hydrogel preparation, and particularly relates to a hydrogel loaded with semaglutide and a preparation method and application thereof. The preparation method comprises the following steps: adding ferulic acid modified chitosan into deionized water to obtain a modified chitosan solution, adding oxidized dextran into deionized water, ultrasonic dissolving to obtain an oxidized dextran solution, adding semaglutide into the oxidized dextran solution to obtain an oxidized dextran mixed solution, and mixing the modified chitosan solution and the oxidized dextran mixed solution to obtain the hydrogel loaded with semaglutide. The hydrogel loaded with semaglutide has the advantages of short gelation time, good injection performance, non-toxicity and good biocompatibility. The hydrogel can significantly reduce myocardial interstitial fibrosis after myocardial infarction and improve the ejection capacity of the heart after myocardial infarction. The hydrogel can be used for preparing drugs for treating myocardial infarction.

The invention belongs to the technical field of bioengineering, and particularly relates to a construction method and application of an animal model of infant renal consumption disease. According to the construction method of the animal model for the infant type renal consumptive disease, provided by the invention, the renal tubule NPHP3 gene of an experimental animal is knocked out to obtain the animal model of which the renal tubule NPHP3 gene is specifically knocked out, and the animal model is recorded as Nphp3flox / -and Cdh16-Cre +. Nphp3flox- / -and Cdh16-Cre + mouse models have obvious renal cyst and interstitial fibrosis 2 weeks after growth, serum creatinine and urea nitrogen increase from 3 weeks, and more than 5-8 weeks of death, so that compared with previously reported genetic engineering mice, the model better conforms to clinical characteristics of human infant renal consumption diseases, and a foundation is laid for subsequent research on pathogenesis and intervention effect.

The invention discloses application of a calcimimetic agent in preparation of a medicine for treating autosomal dominant polycystic kidney disease. Pax8rtTA is adopted; tetOCre is taken as a starting material; after a Pkd1fl / fl mouse model is treated by a calcimimetic cinacalcet, by inhibiting secretion of parathyroid hormone, abnormal activation of ciliary positioning Pth1r is reduced, the progress of the polycystic kidney disease is delayed, and the medicine can remarkably delay cyst growth, improve related indexes of renal functions and has a significant clinical application prospect. The abnormal proliferation of cyst epithelial cells and the interstitial fibrosis process of the kidney are effectively inhibited.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

Activated cardiac fibroblasts are essential for the production of extracellular matrix proteins that accumulate during cardiac fibrosis, and PW1+ cardiac adult stem cells were recently proposed as a cellular source of fibroblasts in the ischemic hearts. Here the inventors identify αV-integrin (or CD51) as an essential regulator of PW1+ cardiac adult stem cells fibrogenic behavior. Inhibition of αV-integrin reduce the profibrotic gene expression profile and the ability to differentiate into fibroblasts of cardiac PW1+ cells. The pharmacological blockade of αV-containing integrins improved cardiac function and survival after MI by reducing infarct size and attenuating the extension of reactive cardiac fibrosis. Notably, the total cardiac fibrotic area as well as interstitial fibrosis in the remote myocardial area are significantly reduced after pharmacological blockade of αV-containing integrins. These data identify a new mechanism that regulates cardiac fibrosis in response to an ischemic injury and suggest that pharmacological targeting of αV-integrin may provide clinical benefit in the treatment of cardiac fibrosis.

The invention belongs to the technical field of hydrogel preparation, and particularly relates to a semeglutide-loaded hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: adding ferulic acid modified chitosan into deionized water to obtain a modified chitosan solution, adding oxidized dextran into the deionized water, carrying out ultrasonic dissolution to obtain an oxidized dextran solution, adding semeglutide into the oxidized dextran solution to obtain an oxidized dextran mixed solution, and carrying out ultrasonic dispersion on the oxidized dextran mixed solution to obtain a modified dextran solution; and mixing the modified chitosan solution and the oxidized dextran mixed solution to obtain the hydrogel. The semeglutide-loaded hydrogel disclosed by the invention has the advantages of short gelation time, good injection performance, no toxicity and good biocompatibility, can obviously relieve myocardial interstitial fibrosis after myocardial infarction and improve ejection capacity of heart after myocardial infarction, and can be used for preparing medicines for treating myocardial infarction.

The application discloses application of an E3 ubiquitin ligase SIAH2 inhibitor in preparation of a lupus nephritis kidney protection drug. Researches of the application show that the SIAH2-LATS2 axis participates in the pathogenic process of kidney fibrosis of lupus nephritis, and it is confirmed that LATS2 can be used as a target point for preventing fibrosis progression in lupus nephritis. It is shown that LATS2 is abnormally down-regulated in lupus nephritis, and the use of an E3 ubiquitin ligase SIAH2 inhibitor can restore the LATS2 level, reduce the production of a LATS2 downstream gene CTGF, reduce the occurrence of interstitial fibrosis, reduce the proteinuria effect of lupus nephritis, thereby protecting the kidney function and delaying the progression of lupus nephritis. The application uses the SIAH2 inhibitor vitamin K3, which can prevent the conversion of lupus nephritis to ESRD, and can be used as an effective drug for treating and preventing kidney fibrosis, and provides a new selection for lupus nephritis treatment drugs and fibrosis prevention and treatment drugs.

The invention provides application of gamma-linolenic acid in preparation of a medicine for preventing or treating diabetic cardiomyopathy. In-vivo and in-vitro experimental results show that the gamma-linolenic acid has a better effect in diabetic cardiomyopathy, which is mainly reflected in reducing oxidative stress (reducing lipid peroxidation), increasing expression of GSH and HO-1, reducing expression of MDA and Nrf2, increasing left ventricular ejection fraction (LVEF) and shortening fraction (FS), and repairing myocardial interstitial fibrosis. Therefore, the gamma-linolenic acid has the potential of being developed into the medicine for treating the diabetic cardiomyopathy.

The invention provides an early screening system for pulmonary interstitial fibrosis based on big data analysis. The early screening system comprises a data acquisition module, a model inspection module, a data preprocessing module, a data storage module, a data analysis module and a result output module. According to the system, a pulmonary interstitial fibrosis early screening model is constructed based on historical data, big data analysis is performed on features extracted from medical image data of a patient according to the model, so that wrong features are eliminated, a data analysis module is used for calculating pulmonary interstitial fibrosis feature coefficients for the correct features, and the accuracy of the pulmonary interstitial fibrosis early screening is improved. The accuracy of the calculation result is improved, the evaluation based on the calculation result can assist a doctor in more accurately identifying the early characteristics of the pulmonary interstitial fibrosis, the accuracy of early diagnosis is improved, and missed diagnosis and misdiagnosis conditions are reduced.

The present invention relates to a novel salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, and a pharmaceutical composition containing same. In the results of a comparison with hydrochloride salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol and the other salts thereof, the novel salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,3-diol, according to the present invention, exhibits excellent effects in all of low hygroscopicity, standard stock solution stability, photostability, oxidation stability, pH-dependent stability, solubility and the like. The pharmaceutical composition, of the present invention, containing the novel salt as an active ingredient, can be effectively used for preventing or treating multiple sclerosis, ischemic stroke, focal segmental glomerulosclerosis (FSGS), inflammatory bowel disease, interstitial fibrosis and tubular atrophy (IFTA) or alopecia areata (AA).

The invention discloses an application of lncRNA-NONMMUG023935 and an inhibitor of the lncRNA-NONMMUG023935 in regulation and control of diabetic nephropathy, and belongs to the technical field of biomedicine. It is found for the first time that MSC inhibits expression of lncRNA-NONMMUG023935 in a high glucose-induced renal tubular epithelial cell EMT model, so that epithelial-mesenchymal transformation and expression of TGF-beta and TNF-alpha are inhibited, and the effect of resisting renal tubular interstitial fibrosis is achieved. According to the discovery, the lncRNA-NONMMUG023935 can be used as a potential treatment target of the diabetic nephropathy, and can play an important role in diagnosis and treatment of the diabetic nephropathy, so that the lncRNA-NONMMUG023935 has a good practical application value.

The application provides a photobiomodulation method for improving high-sugar-induced human renal tubular epithelial cell damage, the photobiomodulation method comprising the step of treating high-sugar-induced human renal tubular epithelial cells by light irradiation; the light irradiation simultaneously satisfies the following conditions: light irradiation wavelength 530nm-1050nm, energy density 2-10J / cm 2 And power density 10-50mw / cm 2 ; the application also comprises the application of the photobiomodulation method in the preparation of a non-drug intervention product for improving high-sugar-induced renal tubular epithelial cell damage, and in the preparation of a drug or auxiliary treatment instrument for improving diabetic nephropathy; the photobiomodulation method can regulate cell activity, inhibit the level of interstitial fibrosis and related signal pathways, and become a potential treatment method for DKD.

The invention discloses a chronic kidney disease interstitial fibrosis and cellular crescent body prediction model and application thereof. The prediction model comprises a kidney interstitial fibrosis prediction model and a cellular crescent body prediction model. The renal interstitial fibrosis prediction model is Logit (P1) =-0.035 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >) + 0.030 * albumin (g / L)-0.039 * hematocrit (%) + 0.036 * RBC distribution width SD (fL)-0.212 * CD4 + / CD8 + T lymphocyte ratio + 0.313; wherein P1 is a severe renal interstitial fibrosis probability value; the cell crescent body prediction model is Logit (P2) =-0.032 * age (age)-0.766 * sex-1.047 * high density lipoprotein (mmol / L)-0.011 * estimated glomerular filtration rate (ml / min / 1.73 m < 2 >)-0.233 * ln (CD3 + CD4 + T lymphocyte count) (piece / l) + 0.670 * ln (urine erythrocyte count) ( / l) + 1.530; wherein P2 is a cellular crescent body formation probability value. The prediction model provided by the invention greatly improves the prediction ability of renal interstitial fibrosis and cellular crescent body, and has significant clinical application value.

The application discloses use of Bikeli tablets in preparation of a medicine for treating type II diabetic nephropathy, and belongs to the technical field of medicines. The Bikeli tablets can realize systematic treatment of type II diabetic nephropathy through systematic effects of'multi-target and multi-pathway'. The Bikeli tablets can not only control blood sugar and blood uric acid from the source, but also can effectively reduce urine protein and improve kidney function (blood creatinine and urea nitrogen), and directly act on kidney tissues to inhibit the key pathological process of kidney interstitial fibrosis which leads to permanent loss of kidney function. Therefore, the Bikeli tablets are suitable for improving clinical symptoms and functional indexes of DKD, and have long-term therapeutic value of delaying disease progression, protecting residual kidney function and preventing occurrence of end-stage renal disease.

The present application relates to the technical field of electric digital data processing, in particular to a kind of lung interstitial fibrosis diagnostic data intelligent management method, comprising: collecting lung interstitial fibrosis diagnostic data;According to the size of each data of all data points, the possibility that each data point represents diagnostic data corresponds to abnormal diagnostic data is obtained, and the threshold of the least number of neighborhood samples is adaptively obtained;According to the threshold of the least number of neighborhood samples of each data point and the size of the number of data points contained in neighborhood, it is judged whether each data point is core object;According to core object, DBScan clustering algorithm is completed, and clustering result is obtained, and it is judged whether data point in each clustering cluster is abnormal data according to clustering result.The present application calculates the abnormal degree of lung interstitial fibrosis data, adaptively obtains the threshold of the least number of neighborhood samples of each data point to carry out clustering operation, reaches more accurately to gather abnormal data into a class, and improves the intelligence of lung interstitial fibrosis data management.